| Literature DB >> 33461986 |
F Perry Wilson1,2, Melissa Martin3,2, Yu Yamamoto3,2, Caitlin Partridge4, Erica Moreira4, Tanima Arora3,2, Aditya Biswas3,2, Harold Feldman5, Amit X Garg6, Jason H Greenberg2,7, Monique Hinchcliff8, Stephen Latham9, Fan Li10, Haiqun Lin11, Sherry G Mansour3,2, Dennis G Moledina3,2, Paul M Palevsky12, Chirag R Parikh13, Michael Simonov2, Jeffrey Testani14, Ugochukwu Ugwuowo3,2.
Abstract
OBJECTIVE: To determine whether electronic health record alerts for acute kidney injury would improve patient outcomes of mortality, dialysis, and progression of acute kidney injury.Entities:
Mesh:
Year: 2021 PMID: 33461986 PMCID: PMC8034420 DOI: 10.1136/bmj.m4786
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Fig 1Screenshot of the acute kidney injury (AKI) alert. Creatinine 1 mg/dL=88.42 μmol/L.
Patient characteristics at the time of randomization. Data are presented as median (interquartile range) or count (percent)
| Variables | Usual care (n=2971) | Alert (n=3059) |
|---|---|---|
| Demographics: | ||
| Median (IQR) age (years) | 71.3 (59.4-81.6) | 71 (59-81.7) |
| Female sex | 1440 (48.5) | 1442 (47.1) |
| Black | 462 (15.6) | 484 (15.8) |
| Hispanic | 289 (9.7) | 331 (10.8) |
| Hospital admission characteristics: | ||
| Medical admission | 2280 (76.7) | 2284 (74.7) |
| Patient in the ICU | 961 (32.3) | 962 (31.4) |
| Patient in the emergency department | 108 (3.6) | 93 (3.0) |
| Patient in the ward | 1902 (64.0) | 2004 (65.5) |
| Hospital 1 (urban, teaching) | 1238 (41.7) | 1277 (41.7) |
| Hospital 2 (urban, teaching) | 599 (20.2) | 649 (21.2) |
| Hospital 3 (urban, teaching) | 456 (15.3) | 479 (15.7) |
| Hospital 4 (suburban, teaching) | 292 (9.8) | 275 (9.0) |
| Hospital 5 (suburban, non-teaching) | 278 (9.4) | 276 (9.0) |
| Hospital 6 (suburban, non-teaching) | 108 (3.6) | 103 (3.4) |
| Comorbidities: | ||
| Chronic kidney disease | 1127 (37.9) | 1163 (38.0) |
| Congestive heart failure | 1307 (44.0) | 1351 (44.2) |
| COPD | 1015 (34.2) | 1049 (34.3) |
| Diabetes mellitus | 1197 (40.3) | 1287 (42.1) |
| Hypertension | 2434 (81.9) | 2510 (82.1) |
| Malignancy | 4712 (15.9) | 460 (15.0) |
| Depression | 687 (23.1) | 655 (21.4) |
| Liver disease | 397 (13.4) | 458 (15.0) |
| Laboratory values (median (IQR))*: | ||
| eGFR at admission (mL/min/1.73 m2) | 55.1 (34.2-84.4) | 55.8 (36.6-83.5) |
| Creatinine (mg/dL)† | 1.5 (1.1-2) | 1.5 (1.2-2) |
| Nadir creatinine (mg/dL)†‡: | 1.1 (0.8-1.5) | 1.1 (0.8-1.5) |
| Sodium (mmol/L) | 138 (135-141) | 138 (135-141) |
| Potassium (mmol/L) | 4.2 (3.8-4.6) | 4.2 (3.8-4.6) |
| Chloride (mmol/L) | 102 (98-106) | 102 (98-106) |
| Bicarbonate (mmol/L) | 24 (21-27) | 24 (21-27) |
| Anion gap (mmol/L) | 12 (10-14) | 12 (10-15) |
| Blood urea nitrogen (mg/dL)† | 28 (18-42) | 28 (19-40) |
| White blood cell count (×1000/μL) | 9.8 (7.2-13.5) | 9.8 (7.2-13.8) |
| Hemoglobin (g/dL) | 10.7 (9-12.3) | 10.5 (8.9-12.3) |
| Platelet count (×1000/μL) | 202.5 (149-266) | 200 (144-266) |
| Exposures before acute kidney injury: | ||
| Contrast in prior 72 hours | 586 (19.7) | 623 (20.4) |
| Cardiothoracic surgery in prior 72 hours | 110 (3.7) | 135 (4.4) |
| ACE inhibitor/ARB in prior 72 hours | 626 (21.1) | 670 (21.9) |
| NSAID in prior 72 hours | 403 (13.6) | 388 (12.7) |
| PPI in prior 72 hours | 684 (23.0) | 677 (22.1) |
| Study timing (median (IQR)): | ||
| Time from admission to randomization (hours) | 50.7 (28.8-104.3) | 50.1 (29.8-101.0) |
| Time from AKI to randomization, hours | 0.5 (0.2-1.3) | 0.5 (0.2-1.2) |
| Alert distribution (median (IQR)): | ||
| Unique providers reached | 7 (4-13) | 7 (4-13) |
ACE=angiotensin converting enzyme; AKI=acute kidney injury; ARB=angiotensin receptor blocker; COPD=chronic obstructive pulmonary disease; eGFR=estimated glomerular filtration rate; ICU=intensive care unit; IQR=interquartile range; NSAID=non-steroidal anti-inflammatory drug; PPI=proton pump inhibitor.
Values at randomization unless otherwise specified.
Blood urea nitrogen 1 mg/dL=0.357 mmol/L; creatinine 1 mg/dL=88.42 μmol/L.
Values in the 48 hours before randomization.
Process outcomes stratified by study arm. Unless otherwise specified, outcomes reflect proportion completed within 24 hours of randomization. Results for usual care and alert groups are shown as number (percent) unless otherwise specified; absolute differences are shown as percent (95% confidence interval) unless otherwise specified
| Variables | Usual care (n=2971) | Alert (n=3059) | Absolute difference |
|---|---|---|---|
| Diagnostic and therapeutic investigation: | |||
| Intravenous fluid drip order | 1034 (34.8) | 1174 (38.4) | 3.8 (1.4 to 6.2) |
| Intravenous fluid bolus order | 339 (11.4) | 397 (13.0) | 1 (−0.4 to 2.3) |
| Urinalysis | 444 (14.9) | 519 (17.0) | 1.9 (0.1 to 3.7) |
| Urine output measurement | 2130 (71.7) | 2242 (73.3) | 1.7 (−0.6 to 4) |
| Subsequent creatinine measurement (28 hours) | 2532 (85.2) | 2666 (87.2) | 1.8 (0.1 to 3.6) |
| Kidney consultation (within 14 days) | 710 (23.9) | 727 (23.8) | 0.1 (−2.1 to 2.2) |
| Nephrotoxin use: | |||
| Contrast exposure | 102 (3.4) | 115 (3.8) | 0.3 (−0.6 to 1.2) |
| Aminoglycoside exposure | 19 (0.6) | 14 (0.5) | * |
| Aminoglycoside exposure among those already | 8/20 (40.0) | 5/20 (25.0) | * |
| NSAID exposure | 166 (5.6) | 144 (4.7) | −1 (−2 to 0.1) |
| NSAID
exposure among those already receiving | 129/312 (41.3) | 103/288 (35.8) | −6.7 (−14.4 to 1.0) |
| ACEi/ARB exposure | 425 (14.3) | 424 (13.9) | −0.1 (−1.8 to 1.6) |
| ACEi/ARB
exposure among those already | 326/532 (61.3) | 331/561 (59.0) | −2 (−7.8 to 3.8) |
| Administrative: | |||
| AKI documentation (at end of encounter) | 1871 (63.0) | 2141 (70.0) | 7.0 (4.6 to 9.3) |
| Median (IQR) hospital direct costs ($) | 10 300 (5400-21 900) | 10 600 (5400-22 800) | 400 (229.7 to 1029.7) |
| Median (IQR) hospital total costs ($) | 19 100 (9900-42 500) | 20 100 (10 200-43 600) | 740.5 (287.6 to 1768.7) |
ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; AKI=acute kidney injury; NSAID=non-steroidal anti-inflammatory drug; PPI=proton pump inhibitor.
Too few events for reliable estimates.
Primary and secondary outcomes of interest.* Results for usual care and alert groups are shown as number (percent) unless otherwise specified; absolute difference is shown as percent (95% confidence interval) except for duration of AKI and maximum AKI stage achieved, in which odds ratios (95% confidence interval) are reported
| Variables | Usual care (n=2971) | Alert (n=3059) | Absolute percentage difference |
|---|---|---|---|
| Primary outcome: | |||
| AKI progression,† dialysis or death at 14 days | 622 (20.9) | 653 (21.3) | 0.6 (−1.4 to 2.7) |
| Secondary outcomes: | |||
| AKI progression† at 14 days | 461 (15.5) | 487 (15.9) | 0.5 (−1.3 to 2.3) |
| Dialysis at 14 days | 93 (3.1) | 106 (3.5) | 0.3 (−0.6 to 1.1) |
| Death at 14 days | 265 (8.9) | 272 (8.9) | −0.3 (−1.7 to 1.1) |
| Discharge to home | 1494 (50.3) | 1503 (49.1) | −1.4 (−4 to 1.1) |
| Discharge to inpatient or home hospice | 165 (5.6) | 173 (5.7) | 0.06 (−1.1 to 1.2) |
| Median length of stay (IQR; days after randomization) | 4.2 (2.1-9.3) | 4.3 (2.2-9.2) | 0.1 (−0.2 to 0.3) |
| Duration of AKI (days): | 0.9 (0.8 to 1) | ||
| <2 | 2108 (71.0) | 2239 (73.2) | |
| 2-<7 | 722 (24.3) | 700 (22.9) | |
| ≥7 | 141 (4.7) | 120 (3.9) | |
| Max AKI stage achieved: | 1 (0.9 to 1.1) | ||
| 0 | 5 (0.2) | 6 (0.2) | |
| 1 | 2302 (77.5) | 2376 (77.7) | |
| 2 | 403 (13.6) | 412 (13.5) | |
| 3 | 261 (8.8) | 265 (8.7) |
Eleven individuals who were randomized never developed AKI, owing to laboratory errors in creatinine measurement, allowing patients to meet AKI criteria, which were subsequently revised lower after enrollment.
Progression of acute kidney injury (AKI) was defined as achieving a higher Kidney Disease: Improving Global Outcomes (KDIGO) AKI stage than the one present at the time of randomization, dialysis, or both.
Fig 2Primary and secondary outcome events, stratified by hospital type. Error bars are 95% confidence intervals of the observed proportion of events. AKI=acute kidney injury
Fig 3Prespecified subgroup analyses show similar alert effect across a diverse array of patient characteristics. Diamonds reflect relative risk, with bars showing 95% confidence interval. Creatinine 1 mg/dL=88.42 μmol/L. ICU=intensive care unit